Dexcel Pharma is a privately owned pharmaceutical company developing, manufacturing, and commercializing innovative and generic products worldwide.

Dexcel Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Ltd. Ordinary Shares

UroGen Pharma is focused on developing treatments for urological cancers. The company is involved in the creation of therapies and has reported progress in its clinical trials.

UroGen Pharma

UroGen Pharma | 10,665 followers on LinkedIn. UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. 

Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs.

Will Batenic

VP Quality at UroGen Pharma

Sasha Nezlin

Solutions Architect | Technologist | AI Explorer | Digital Marketer | Agile Dev Ops enabler

Kal Mirza, MEng CSM

Christine Cassiano

We’re sharing our 2024 Q3 financial results in a live, recorded webcast today at 10am ET. Tune in to hear the updates: https://bit.ly/4feDk9M

See UroGen’s 2024 Q3 financial results during a live webcast on November 6 at 10:00 AM ET. Click below to tune in: https://bit.ly/3BY3H4T

The Bladder Cancer Advocacy Network (BCAN) brings together #bladdercancer patients, survivors, and caregivers to share their unique experiences. We’re proud to sponsor the 2024 Fall BCAN Summit for Patients and Families, an important event supporting the bladder cancer community. Learn more: https://bcan.org/

In this episode of The UroGist, join Michael Louie, MD MPH MSc , and Jennifer Linehan, MD , as they dive into how antegrade administration is used for a low-grade upper tract urothelial cancer treatment. Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX

The Journal of Urology published 12-month duration of response data from the ENVISION study, which examines our investigational treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). See the results: https://bit.ly/4hfOzQy

Tune into our first episode now live on The UroGist to hear our own, Michael Louie, MD MPH MSc and Dr. Katie Murray, Chief of Urology Service at Bellevue Hospital Center and Associate Professor at NYU Langone Health discuss the treatment paradigm for low-grade upper tract urothelial cancer patients. Listen to The UroGist on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX

We are thrilled to announce the launch of our new podcast for urologists, The UroGist! In each episode, Michael Louie, MD MPH MSc will be joined by an expert guest to discuss the latest research and treatment challenges in urologic oncology. Listen now on Spotify: https://spoti.fi/4eNYkUA or Apple Podcasts: https://bit.ly/3Uei6QX

Today we announced the acceptance of the completed New Drug Application to the U.S. FDA for UGN-102, our investigational treatment in development for low-grade intermediate-risk non-muscle invasive #bladdercancer . Learn more: https://bit.ly/4dL8OTf

We’re excited to welcome Chris Degnan as UroGen’s new Chief Financial Officer. With over a decade of experience in financial strategy and management, Chris will help build long-term growth during UroGen’s next chapter. Learn more: https://bit.ly/47X8Y8X

We are pleased to announce the first patient has been dosed in our Phase 3 UTOPIA study, a clinical trial evaluating our investigational drug UGN-103, in patients with low-grade intermediate-risk non-muscle invasive #bladdercancer . Learn more here: https://bit.ly/4gLiRdP

Metric
Company Name	Dexcel Pharma
Symbol
MSH ID	COM:DEXCEL
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	IL
Stage
Employee Count
Website	dexcel.com
LinkedIn	dexcel-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:UROGEN

UroGen Pharma

Last Close

11.55

22/11 21:00

Market Cap

502.60M

Beta: -

Volume Today

390.58K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue